The firm, which said last week it expected to raise $15.9 million, has said it will use the net proceeds for working capital and general corporate purposes.
The increase was largely due to a 13 percent rise in clinical lab revenues, driven by sales of molecular diagnostic tests, particularly in women's health.
Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.
Ampath will be one of the first laboratories in South Africa to offer a CE-IVD accredited noninvasive prenatal testing center and will act as a hub for such services.
The agreement will open markets in Denmark, Sweden, and Norway for SpeeDx's STI detection product lines.
The funding will be used to pay for clinical trials in the US that will be used as underlying evidence for FDA clearance of the test, the company said.
The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.
Asia Genomics will distribute NantHealth's cancer molecular profiling service in Singapore, Malaysia, Thailand, Vietnam, and the Philippines.
The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.
The company credited its molecular diagnostics and international businesses as drivers of new growth.
Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.
Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.
Researchers link genetic links between education and smoking and longevity.
In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.